Eng Ppt (三元基因管理层演示报告) 20090222

Beijing Tri-Prime Genetic
Engineering Co. Ltd.
Presented by
Mr. Cheng, Yongqing (Founder, CEO)
Feb. 23th, 2009
1
9bhk0273_ss.ppt
Content
Company history
Investment highlights
Innovative technologies
Innovative business model
Growth strategy
Company history
Unique product with market leading position and high
brand recognition
Extensive distribution network with China - specific marketing
strategy
Strong product life-cycle management; robust pipeline with near

term product launch potential
Highly efficient GMP approved production process
Professional reputation; strong established relationships with
customers/suppliers as well as government authorities
Innovative and experienced management team
Content
Company history
Growth strategy
Founder Dr. Hou, Yunde

Education:
1955
1962
Dr. Hou Yunde
Graduated from Tongji medical University

Obtained MD from Soviet Academy of Medical Sciences
Work experience:
1985-1996
Institute chief, Virology Institute, China Academy of
Preventive Medical Sciences
Chief, Virus Research Center, WHO
Chief, the State Key Lab of Viral Gene Engineering
19861996
Chief scientist of Bio Tech, Chinese National Programs for
High Technology Research and Development
1992-1998
Chairman of the Board, Beijing Tri-Prime Genetic Engineering
Co., Ltd. (Tri-Prime Gene)
1998-current Vice President, China National Academy of Engineering,
Academician, China Academy of Engineering
2008-current Chief Scientist, infectious diseases program, Ministry of
Health
Hapgen
Hapgen (Interferon-alpha1b), Tri-Prime Genes key product, was approved by
Chinese authority (predecessor of SFDA) in 1989 as a Class I new drug
The gene of Hapgen was cloned by Professor Yunde Hou from leukocyte of healthy
Chinese people, and subsequently named as Interferon 1b by relevant international

professional committees
Hapgen was produced in E.coli expression system and purified through a multi-steps
process
Hapgen inhibits intracellular virus replication and tumor cells proliferation efficiently,
and stimulates the immune system as well
The indications approved are chronic hepatitis type B and type C, condyloma
acuminatum, and hairy cell leukemia
Since its introduction, patients treated with Hapgen showed much lower neutralizing
antibody rate and less side effects comparing to similar interferon products
Tri-Prime Gene has patented the production of Hapgen, and the product has been
awarded SFDA protected medicine
Hapgen revenue growth
2008 China Interferon

product market share
6500
5500
Antefen
18.53%
4500
3500
Intelong
8.77%
Anfulon
20.95%
Kaiwin
18.84%
2500
1500
Sinogen
2.65%
500
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
-500
8
9bhk0273_ss.ppt
Hapgen
23.09%
Intefen
7.15%
Founder Mr. Cheng, Yongqing
Unique product with market leading position and high brand
recognition
Extensive distribution network with China - specific

marketing strategy
10
Extensive distribution network

Heilongjiang
30 provinces and 16
cities / districts in China
Jilin
Innermongolia
Liaoning
XinJiang
Ningxia
Beijing
Tianjin
Hebei
Shanxi
Shandong
Qinghai
Gansu Shaanxi Henan
Sichuan
Chong
Hubei
-qing
Jiangsu
Shanghai
Anhui
Zhejiang
Hunan
Guizhou
Yunnan
Jiangxi
Fujian
Guangdong
Guangxi
Hainan
11
9bhk0273_ss.ppt
20 dealers and 120

distributors
204 professional
salespeople covering
736 hospitals and 4,369
doctors
Distribution channels and

management model
Marketing team
Dealers
Offices
Xinjiang
Shanxi
Hainan
Guangxi
Fujian
Yunnan
Shaanxi
Jiangxi
Henan
160 regions / cities, 736 hospitals, and

4,369 doctors
Hebei
zhejiang
Liaoning
Jilin
Helongliang
Gansu
12
Inner Mongolia
Sichuan
Shanghai
Hubei
Guizhou
Tianjin
Hunan
Chongqing
An Hui
S. Jiangsu
N. Jiangsu
Shandong
Guangdong
Beijing
204 medicine representatives via 20

dealers and 120 distributors
recognition
Extensive distribution network with China-specific marketing
strategy
Strong product life-cycle management; robust pipeline

with near term product launch potential
13
Hapgen Product Life-Cycle

Interferon 1b spray
Interferon 1b eye drops
Albumin-free formula of
Hapgen
New indications - pediatric
pneumonia
Large dose interferon 1b
Long-acting interferon
inhaled Interferon 1b
powder
G2 long-acting interferon
Small interfering RNA
2009
2010
2011
2012
14
2013
2014
2015
Site-specific
PEGylated
interferon
Success factors
Technology
oriented
Proven track
record in new
products
developments
15
Market
oriented
recognition
Extensive distribution network with China specific marketing
strategy

16
GMP
standardized
production
system
Highly efficient and flexible

production process
Injection
powder
Bacterial
strain
Fermentation
Purificatio
n
Injection
liquid
Packaging
Eye
drops
Spray
17
Patented
formula
recognition
strategy
Professional reputation; strong established

relationships with customers/suppliers as well as
government authorities
18
Cooperation with China Hepatitis

Prevention and Control Foundation
19
9bhk0273_ss.ppt
License for A-grade enterprise in terms of taxation credit

20
9bhk0273_ss.ppt
Certificate for High-technology Enterprise

21
9bhk0273_ss.ppt
Projects awarded governmental

subsidies
Sponsor
Projects
Duration
Amount
Research on a New Anti-cancer Drug: sApo-2L

Volume Production of Nucleic Acid and Polypeptide
Medicine
Development of a New System for Recombinant Human
Interferon
New Dosage Form of 1b Recombinant Human
Interferon Liposome
Gene Engineering-based Calcitonin Production
Research on PKU Oral Preparation
2002-2005
2008-2009
RMB600,000
RMB900,000
2008-2010
RMB2.0 million
1999-2002
RMB500,000
2000-2003
2006-2009
RMB1.0 million
RMB1.2 million
High Efficiency Super Interferon
2003-2005
RMB1.0 million
PEGylated New type Interferon
2005-2006
RMB1.0 million
Research on Humanized Monoclonal Antibody against

VEGF
Fc Fusion Protein of a New Anti-cancer Drug-sApo2L
2005-2006
RMB800,000
2006-2009
RMB650,000
Clinical Research on High Performance Consensus

interferon
Clinical Research on Interferon for Infant Pneumonia
2006-2009
RMB3.0 million
2006-2009
RMB900,000
Construction of Corporate R&D Centers

R&D of Interferon Aerosol
2008-2009
2007-2009
State-level projects
National 863 Program
National 863 Program Key Project
National Project of New Medicines Development
Innovation Fund, Ministry of Science and Technology
Provincial-level projects
Specific Industrial Project of Beijing Municipal Development
and Planning Commission
Key Project of the Beijing Science and Technology
Development Plan
Development Plan
Development Plan
Development Plan
Development Plan
Science and Technology Project for Daxing District of Beijing
Science and Technology Project for Daxing District of Beijing
22
9bhk0273_ss.ppt
recognition
strategy
23
9bhk0273_ss.ppt
Experienced management team

Tri-Prime Gene is led by a team with vision, courage and
strong organizational capability
The management team uses innovative technologies and
business models to navigate the Company through rapidly
changing market environment and built its core
competitiveness for sustainable development
These factors are fundamental to Tri-Prime Genes
continuous growth and success
24
9bhk0273_ss.ppt
Evolution
of policy
Evolution
of population
Economic cycles
and industry policies
Global medical market

Chinese medical market
Medical industry
Trade
policies
and
tax policies
Technology
development
Medical
system
Enterprises
Labor market and

welfare policies
25
9bhk0273_ss.ppt
Healthcare
system
Public
health
and
environment
protection
Evolution
of society
Innovative technology and

business model
History and experience showed the growth of an enterprise depends
not only on its own effort, but also the business environment it is in. To
establish sustainable and competitive advantages in a new business
environment, an enterprise must take the following methods:
Develop customer focused high value products

Efficiently use the companys internal and external resources
Build sustainable and cooperative relationship with key parties
Establish innovative technology and business models that adapt
to the ever changing market environment
26
9bhk0273_ss.ppt
Content
Company history
Growth strategy
27
9bhk0273_ss.ppt
R&D pipeline
Approval for
clinical trials
Lab
Animal experiments
Approval for clinical trials
Approval for
production
Clinical trials
Approval for production

Interferon 1b spray
Interferon 1b eye drops
pediatric pneumonia
High dose interferon 1b
Inhaled interferon 1b powder
Long-acting interferon II
Small interfering RNA
Albumin-free formula of Hapgen
28
9bhk0273_ss.ppt
Current progress:
Registration work
Applied as Class I novel medicine, entered special approval
stage
Passed in-site inspection of local Bureau of Drug Supervision
Passed sample inspection of National Institute for the Control
of Pharmaceutical and Biological Products
Currently evaluated by State Food and Drug Administration
Intellectual property
Goals
for 2009:patents
obtain application
approval for
clinical
trials in June
International
under
review
and complete Phase I clinical trials by the end of 2009
29
9bhk0273_ss.ppt
Long-acting interferon design ideas

Accelerated evolution integrated interferon
High-activity interferon
Inducing 1b specific amino acid sequence

High-activity, low-toxicity interferon
Polyethylene glycol (PEG) modification
Long-acting, high-activity and low-toxicity interferon

30
9bhk0273_ss.ppt
Long-acting interferon characteristics

PEG-IIFNm
(Tri-prime Gene)
PEGASYS
(Roche)
PEG-INTRON
(Schering-Plough)
Modification strategy
Site specific
Non site specific
Non site specific
Motif for modification
-SH
Free -NH2
-NH2-SH-OH
etc.
>9
Homogeneous
Heterogenous
Heterogenous
20kD
40 kD
12 kD
Analysis
method
SEC-HPLC
RP-HPLC
SEC-HPLC
Quality
criterion
Monomer95%
Oligomer 3.0%
Free IIFNm1.0%
Monomer 96%
Oligomer 3%
Others 1%
Monomer 85%
Oligomer 10%
Free IFN 5%
Iodine or commassie
blue staining
Iodine staining
Iodine staining
> 3.0106 IU/mg
1.0106 IU/mg
2.0107IU/mg
ng
N/A
N/A
11 folds increased in
animal
human
human
Number of modification site

Homogeneity
PEG M.W.
Purity
SDS-PAGE staining
Biological activity
PEG residues
Half life
31
9bhk0273_ss.ppt
Interferon 1b
spray
Interferon 1b
eye drops
Indications
Skin herpes simplex
Indications
Herpes simplex virus infection in eyes,
Virus infection related primary or

recurrent herpes labialis and genital
including herpes simplex keratitis,

conjunctivitis, blepharitis, etc.
herpes
Specifications
Specifications
20g/2ml
25g/5ml
Dosing
Dosing
For acute inflammation treatment: one drop
1-2 spray per dose, three times per day,
per dose, 4-6 doses per day
7 days per course
Decrease to 2-3 doses or 1 dose per day in

one or two weeks
Two bottles for each course of treatment
32
9bhk0273_ss.ppt
Other new products

Project
1. New indications
expansion for
low-dose Hapgen
Indication
Method of
applying
Pediatric viral
Aerosol
pneumonia
inhalation
R&D
Advantages
stage
High safety and mild side effect ;
the first clinical trial for pediatric
Phase I
respiratory disease in China
2. New indications
expansion for
high-dose
Renal cancer,
im
lymphoma, etc.
High safety and mild side effect;
Phase I
exploit tumor therapy market
Hapgen
3. 2nd generation of
long-acting
Laboratory
Viral hepatitis
im
Administration every two weeks

screening
interferon
4. Inhaled
interferon 1b
powder
5. siRNA
Viral hepatitis,
pneumonia
Viral hepatitis
inhalation
im
33
9bhk0273_ss.ppt
Substitute injection
Application of edge-cut technique in

the area of hepatitis therapy
preclinical
preclinical
Content
Company history
Growth strategy
34
9bhk0273_ss.ppt
Management vision
Tri-Prime Gene is dedicated to the creation of value for its customers
(patients). The Company respects the professional qualification of its
partners (doctors), and aims to establish mutually beneficial and long
lasting relationships with them. Our goal is to create a patient focused
business environment with the available social resources.
Provide customers (patients) with cost effective and efficacious
products
Establish sustainable relationship with our partners (doctors)
through high academic/commercial value projects
Manage resources from all aspects (governmental and nongovernmental); use innovative business model to create
socially responsible products
35
9bhk0273_ss.ppt
Product-oriented sales model
Company
Sales
representatives
36
9bhk0273_ss.ppt
Doctors
Customer-oriented sales model

Healthcare policy
development
Industry
suggestion
Healthcare business
development
Government
regulator
Set up academic topic

Clinic Research
Nationwide academic/
scientific promotion
Institute
organization
Department meeting
Academic visit
research
Company
Scientific
promotion
Professional training
Hospital
Doctor
Academic support
Service support
Patient education in hospital

Patient education in
community
Patient education
patient
Service network platform
Patient database
37
9bhk0273_ss.ppt
Evidence-based promotion model

Company sales representatives use evidence-based
promotional methods
Academic seminars for dealers and distributors
Ideas
Academic
authority/expert
Clinical trials
Medical
application
Professional
scientific seminar
38
9bhk0273_ss.ppt
Sales (RMB)
Net income (RMB)
70,000,000
14,000,000
60,000,000
12,000,000
50,000,000
10,000,000
40,000,000
8,000,000
30,000,000
6,000,000
20,000,000
4,000,000
10,000,000
2,000,000
0
2006
2007
2008
39
9bhk0273_ss.ppt
2006
2007
2008
Content
Company history
Growth strategy
40
9bhk0273_ss.ppt
Growth strategy
During the past 16 years, Tri-Prime Gene management
team has successfully navigated the Company through the
highly competitive and uncertain China healthcare industry

Tri-Prime Gene team leads with the principle of active
product management, asset management and capital
management
This flexible approach to business model and technology
management has led Hapgen to become one of the most
successful protein drugs on Chinese market
41
9bhk0273_ss.ppt
Growth strategy
Product management involves the research, development, manufacturing and marketing of
Product
existing and pipeline products. The goal is enhancing product profitability by increasing market
management
share and brand awareness. Performance review criteria: revenue growth, market share, profit
margin, etc
Asset
management
Assets management focuses on increasing efficiency and profitability of the Companys

tangible and intangible assets. Intangible assets include customer relationship, goodwill,
industrial expertise, administrative resources, know-how and experienced and innovative team
Capital management focuses on enhancing companys market value by following sustainable
Capital
management
development strategy. Capital management activities includes: financing activities such as

private placement, IPO, and other investment/M&A projects. Performance review criteriaROI,
investment recovery period, etc
42
9bhk0273_ss.ppt
Thank you!
43
9bhk0273_ss.ppt

Eng Ppt (三元基因管理层演示报告) 20090222

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Eng Ppt (三元基因管理层演示报告) 20090222

Uploaded by

Copyright:

Available Formats

Beijing Tri-Prime Genetic

Engineering Co. Ltd.

Strong product life-cycle management; robust pipeline with near

Founder Dr. Hou, Yunde

Dr. Hou Yunde

Graduated from Tongji medical University

Chinese people, and subsequently named as Interferon 1b by relevant international

Hapgen revenue growth

2008 China Interferon

Founder Mr. Cheng, Yongqing

Extensive distribution network with China - specific

Extensive distribution network

20 dealers and 120

Distribution channels and

160 regions / cities, 736 hospitals, and

204 medicine representatives via 20

Strong product life-cycle management; robust pipeline

Hapgen Product Life-Cycle

Small interfering RNA

Highly efficient GMP approved production process

Highly efficient and flexible

Professional reputation; strong established

Cooperation with China Hepatitis

License for A-grade enterprise in terms of taxation credit

Certificate for High-technology Enterprise

Projects awarded governmental

Research on a New Anti-cancer Drug: sApo-2L

High Efficiency Super Interferon

PEGylated New type Interferon

Research on Humanized Monoclonal Antibody against

Clinical Research on High Performance Consensus

Construction of Corporate R&D Centers

Innovative and experienced management team

Experienced management team

Global medical market

Labor market and

Innovative technology and

Develop customer focused high value products

Approval for clinical trials

Approval for production

Small interfering RNA

Albumin-free formula of Hapgen

Long-acting interferon design ideas

Inducing 1b specific amino acid sequence

Polyethylene glycol (PEG) modification

Long-acting, high-activity and low-toxicity interferon

Long-acting interferon characteristics

Non site specific

Non site specific

Motif for modification

> 3.0106 IU/mg

Number of modification site

Virus infection related primary or

including herpes simplex keratitis,

1-2 spray per dose, three times per day,

per dose, 4-6 doses per day

7 days per course

Decrease to 2-3 doses or 1 dose per day in

Other new products

respiratory disease in China

High safety and mild side effect;

exploit tumor therapy market